Advances in Targeted Therapy for Dermatofibrosarcoma Protuberans
Author Information
Author(s): Piotr Rutkowski, Agnieszka Wozniak, Tomasz Switaj
Primary Institution: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Hypothesis
The molecular pathogenesis of dermatofibrosarcoma protuberans (DFSP) can be targeted with specific therapies.
Conclusion
Imatinib is considered the gold standard treatment for inoperable, metastatic, or recurrent cases of DFSP, showing significant efficacy.
Supporting Evidence
- Imatinib showed responses in all patients in a study of 10 patients with advanced DFSP.
- Complete responses were observed in five out of ten locally advanced cases treated with imatinib.
- Imatinib therapy resulted in a clinical benefit rate exceeding 70% in pooled analyses of phase II trials.
Takeaway
Doctors found a special medicine called imatinib that helps treat a rare skin cancer called dermatofibrosarcoma protuberans, making it easier for some patients to have surgery.
Methodology
The study involved clinical trials assessing the efficacy of imatinib in patients with advanced DFSP.
Potential Biases
Potential bias may arise from the small sample size and the nature of clinical trials.
Limitations
The study's findings may not be generalizable due to the limited number of patients and the specific nature of the trials.
Participant Demographics
Patients included those with advanced, inoperable, or recurrent DFSP.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website